万方发展(000638.SZ):子公司与中科院苏州医工所签署战略合作协议
格隆汇 3 月 15日丨万方发展(000638.SZ)公布,公司控股子公司万方百奥(乙方)于2021年3月11日与中科院苏州医工所(甲方)签订《战略合作协议》,约定双方合作共建“中科院苏州医工所万方百奥生物技术研究中心/实验室”(“研究中心”),以技术为牵引、市场需求为目标,合作研发双方认同的高端医疗器械、疫苗免疫效果评价和第三方检测试剂等相关产品,共同组成一支紧密合作的研发、工程化、产业化团队,形成一批具有自主知识产权的成果和技术。
甲、乙双方对包括但不限于生物医药、疫苗、疫苗免疫评价、高端医疗器械、第三方检测平台等领域的市场前景一致看好,且各方在该领域的合作能充分发挥各自的优势与核心竞争力。其中甲方已建成科技创新与工程化的研发平台,在研发疫苗免疫效果评价方法和第三方检测试剂等方面取得了部分阶段性成果;乙方拥有国内领先的生物技术研发及转化平台建设解决方案,拥有疫苗、重组蛋白类药物、疫苗免疫效果评价方法、第三方检测平台等产品的开发、生产、销售及市场能力。
此次战略合作协议的签署,有利于公司迅速搭建与中科院合作的科研平台,并联合其专业的科研团队和研发平台,加快在高端医疗器械创新技术、疫苗免疫效果评价和第三方检测试剂等领域取得自主知识产权成果并实现产业化落地,拓宽公司在生物制品板块的布局,符合全体股东的利益和公司长远发展战略。公司预计该项合作短期内不会对公司的财务状况造成重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.